The disruptive force of weight loss drugs: How GLP-1s do more than shed pounds

The rising popularity of weight-loss drugs, specifically GLP-1s, is reshaping the economic landscape in the United States, extending far beyond individual health and well-being. As of November, one in eight adults are using these medications to lose weight or manage a chronic condition, according to a KFF survey.

A Billion-Dollar Industry

The Financial Impact

The GLP-1 industry is experiencing substantial growth, generating over $31 billion in revenue for Danish pharmaceutical company Novo Nordisk in 2024. This figure represents a significant portion of Denmark’s GDP, as reported by Reuters. Celebrities have publicly endorsed and admitted to using these products, further fueling their cultural prominence and driving demand.

Ripple Effects Across Industries

Shifting Consumer Spending

Studies indicate that GLP-1 use is correlated with decreased spending on groceries and fast food. Registered dietitian Nicolette Pace notes that patients often report reduced appetite and overall food consumption. Dr. Will Haas, an integrative medicine physician, explains that these medications can also impact the brain’s “reward centers,” curbing cravings for ultra-processed foods.

A study published in the Journal of Market Research found that households with at least one GLP-1 user experienced a more than 5 percent drop in grocery spending within six months. Bain & Company research reveals that U.S. Consumers taking GLP-1s spend an average of 5 percent less on fast food.

Impact on Other Sectors

The effects extend beyond food. GLP-1 users are also reportedly cutting back on alcohol consumption, with approximately 44 percent drinking less after starting medication, and 82 percent maintaining those habits even after stopping, according to a survey by EY-Parthenon. This shift may be contributing to a downturn in alcohol stock values, as noted by Forbes.

Even the airline industry could benefit, as slimmer passengers translate to lower fuel costs, potentially saving top U.S. Airlines up to $580 million annually, according to Jefferies. The fashion industry is also experiencing disruption, with a rise in sales of smaller clothing sizes and an increase in returns, as reported by Impact Analytics.

What’s Next?

food companies will continue to adapt their marketing strategies, labelling products as “GLP-1 friendly,” particularly those high in protein. However, these labels are currently unregulated, and experts like Pace emphasize the importance of reading ingredient lists and consulting with healthcare professionals. Analysts expect that some companies may see continued pressure on sales as GLP-1 usage increases. It’s also possible that fitness industries will see increased demand as patients seek to maintain muscle mass while losing weight.

Frequently Asked Questions

What percentage of U.S. Adults are currently using GLP-1 medications?

According to a November survey by KFF, one in eight adults in the United States are currently taking a GLP-1 drug for weight loss, diabetes, or another condition.

How much revenue did Novo Nordisk’s GLP-1 medications generate in 2024?

Novo Nordisk’s GLP-1 medications, including Ozempic and Wegovy, generated more than $31 billion in revenue in 2024.

What impact are GLP-1s having on grocery spending?

Studies show that households with at least one GLP-1 user saw their grocery spending drop by more than 5 percent within six months, according to a study published in the Journal of Market Research.

As GLP-1 medications continue to gain traction, will businesses across various sectors be able to successfully adapt to these shifting consumer trends?